Literature DB >> 34347563

Electromyoneurography and laboratory findings in a case of Guillain-Barré syndrome after second dose of Pfizer COVID-19 vaccine.

Roberto Scendoni1, Cristina Petrelli2, Giorgia Scaloni3, Francesco Ottavio Logullo2.   

Abstract

Guillain-Barre syndrome (GBS) is an acute immune-mediated disease of the peripheral nerves and nerve roots (polyradiculoneuropathy) that is usually elicited by various infections. We present a case of GBS after receiving the second dose of Pfizer-COVID 19 vaccine. Diagnosis was made after performing an accurate clinical examination, electromyoneurography and laboratory tests. In particular, anti-ganglioside antibodies have tested positive. During this pandemic with ongoing worldwide mass vaccination campaign, it is critically important for clinicians to rapidly recognize neurological complications or other side effects associated with COVID-19 vaccination.

Entities:  

Keywords:  Pfizer-BioNTech COVID-19 vaccine; anti-ganglioside antibodies; electromyoneurography; guillain-barre syndrome; neurological complications

Mesh:

Substances:

Year:  2021        PMID: 34347563      PMCID: PMC8828152          DOI: 10.1080/21645515.2021.1954826

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  9 in total

1.  Anti-ganglioside antibodies in Guillain-Barré syndrome; useful diagnostic markers as well as possible pathogenetic factors.

Authors:  Susumu Kusunoki
Journal:  Intern Med       Date:  2003-06       Impact factor: 1.271

Review 2.  AANEM - IFCN Glossary of Terms in Neuromuscular Electrodiagnostic Medicine and Ultrasound.

Authors:  Reinhard Dengler; Mamede de Carvalho; Nortina Shahrizaila; Hiroyuki Nodera; Steve Vucic; Alexander Grimm; Luca Padua; Stefanie Schreiber; Mary K Kneiser; Lisa D Hobson-Webb; Andrea J Boon; Benn E Smith; William J Litchy; Yuebing Li; Michael Lenihan; V Brandon Thompson; Erik Stalberg; Donald B Sanders; John C Kincaid
Journal:  Muscle Nerve       Date:  2020-04-26       Impact factor: 3.217

3.  Motor nerve terminal degeneration provides a potential mechanism for rapid recovery in acute motor axonal neuropathy after Campylobacter infection.

Authors:  T W Ho; S T Hsieh; I Nachamkin; H J Willison; K Sheikh; J Kiehlbauch; K Flanigan; J C McArthur; D R Cornblath; G M McKhann; J W Griffin
Journal:  Neurology       Date:  1997-03       Impact factor: 9.910

Review 4.  Peripheral neuropathies and anti-glycolipid antibodies.

Authors:  Hugh J Willison; Nobuhiro Yuki
Journal:  Brain       Date:  2002-12       Impact factor: 13.501

Review 5.  Looking beyond COVID-19 vaccine phase 3 trials.

Authors:  Jerome H Kim; Florian Marks; John D Clemens
Journal:  Nat Med       Date:  2021-01-19       Impact factor: 53.440

6.  Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy.

Authors:  Asia Filatov; Pamraj Sharma; Fawzi Hindi; Patricio S Espinosa
Journal:  Cureus       Date:  2020-03-21

7.  Neurological Complications of Coronavirus Disease (COVID-19): Encephalopathy, MRI Brain and Cerebrospinal Fluid Findings: Case 2.

Authors:  Patricio S Espinosa; Zufe Rizvi; Pamraj Sharma; Fawzi Hindi; Asia Filatov
Journal:  Cureus       Date:  2020-05-02

8.  Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.

Authors:  Fernando P Polack; Stephen J Thomas; Nicholas Kitchin; Judith Absalon; Alejandra Gurtman; Stephen Lockhart; John L Perez; Gonzalo Pérez Marc; Edson D Moreira; Cristiano Zerbini; Ruth Bailey; Kena A Swanson; Satrajit Roychoudhury; Kenneth Koury; Ping Li; Warren V Kalina; David Cooper; Robert W Frenck; Laura L Hammitt; Özlem Türeci; Haylene Nell; Axel Schaefer; Serhat Ünal; Dina B Tresnan; Susan Mather; Philip R Dormitzer; Uğur Şahin; Kathrin U Jansen; William C Gruber
Journal:  N Engl J Med       Date:  2020-12-10       Impact factor: 91.245

9.  Neurological Complications of COVID-19: Guillain-Barre Syndrome Following Pfizer COVID-19 Vaccine.

Authors:  Sadia Waheed; Angel Bayas; Fawzi Hindi; Zufe Rizvi; Patricio S Espinosa
Journal:  Cureus       Date:  2021-02-18
  9 in total
  9 in total

1.  Profiling COVID-19 Vaccine Adverse Events by Statistical and Ontological Analysis of VAERS Case Reports.

Authors:  Wenxin Guo; Jessica Deguise; Yujia Tian; Philip Chi-En Huang; Rohit Goru; Qiuyue Yang; Suyuan Peng; Luxia Zhang; Lili Zhao; Jiangan Xie; Yongqun He
Journal:  Front Pharmacol       Date:  2022-06-24       Impact factor: 5.988

Review 2.  COVID-19 and the peripheral nervous system. A 2-year review from the pandemic to the vaccine era.

Authors:  Arens Taga; Giuseppe Lauria
Journal:  J Peripher Nerv Syst       Date:  2022-03-14       Impact factor: 5.188

3.  Sub-acute Onset of Guillain-Barré Syndrome Post-mRNA-1273 Vaccination: a Case Report.

Authors:  Shivaraj Nagalli; Nidhi Shankar Kikkeri
Journal:  SN Compr Clin Med       Date:  2022-01-18

4.  Guillain-Barre Syndrome After Two COVID-19 Vaccinations: Two Case Reports With Follow-up Electrodiagnostic Study.

Authors:  Jun Woo Kim; Yong Gyun Kim; Yu Chan Park; Saemi Choi; Sanggon Lee; Hye Joon Min; Mi Jung Kim
Journal:  J Korean Med Sci       Date:  2022-02-21       Impact factor: 2.153

5.  Facial Diplegia Variant of Guillain-Barré Syndrome in Pregnancy Following COVID-19 Vaccination: A Case Report.

Authors:  Adeel S Zubair; Ju Young Bae; Kunal Desai
Journal:  Cureus       Date:  2022-02-17

6.  Vaccine hesitancy with a history of Guillain Barre Syndrome: Weighing the risks and benefits of SARS-CoV-2 vaccination.

Authors:  Aleksandra Murawska Baptista; Akankcha Alok; Claudia Libertin
Journal:  IDCases       Date:  2022-03-05

7.  Rare occurrence of Guillain-Barré syndrome after Moderna vaccine.

Authors:  Tissa Bijoy George; Aleesha Kainat; Pranali Santhoshini Pachika; Jonathan Arnold
Journal:  BMJ Case Rep       Date:  2022-05-09

8.  Prognosis of Guillain-Barré Syndrome Linked to COVID-19 Vaccination.

Authors:  Shaun Kai Kiat Chua; Qian Ying Soh; Seyed Ehsan Saffari; Eng-King Tan
Journal:  Brain Sci       Date:  2022-05-30

Review 9.  Guillain-Barré syndrome in association with COVID-19 vaccination: a systematic review.

Authors:  Meysam Abolmaali; Fatemeh Rezania; Arman Karimi Behnagh; Negin Mahmoudi Hamidabad; Ali Gorji; Zahra Mirzaasgari
Journal:  Immunol Res       Date:  2022-09-13       Impact factor: 4.505

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.